ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Dechra Pharmaceuticals PLC Director/PDMR Shareholding (0190A)

24/09/2020 10:32am

UK Regulatory


Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Dechra Pharmaceuticals Charts.

TIDMDPH

RNS Number : 0190A

Dechra Pharmaceuticals PLC

24 September 2020

24 September 2020

Dechra Pharmaceuticals PLC

Notification of Transactions by Persons Discharging Managerial Responsibilities

On 24 September 2020, Dechra Pharmaceuticals PLC was notified by a Director of the Company and Persons Discharging Managerial Responsibilities that he had completed the sale of part of his beneficial interest in Dechra.

Tony Griffin, Executive Director, has sold 4,400 ordinary shares in the Company to satisfy long term personal financial planning considerations and widen his investment portfolio. Following this transaction, Tony Griffin will continue to retain a beneficial holding of 70,650 ordinary shares which represents 0.065% of the current issued share capital in the Company.

The Notification of Dealing Form set out below is provided in accordance with Article 19.3 of MAR.

Notification of Dealing Form:

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                                   Tony Griffin 
     -------------------------------------  ---------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position/status                        Director 
     -------------------------------------  ---------------------------------- 
 b)   Initial notification/amendment         Initial Notification 
     -------------------------------------  ---------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------- 
 a)   Name                                   Dechra Pharmaceuticals PLC 
     -------------------------------------  ---------------------------------- 
 b)   LEI code                               213800J4UVB5OWG8VX82 
     -------------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------------- 
 a)   Description of the financial           Ordinary Shares of 1 pence each 
       instrument                             ISIN: GB0009633180 
       Identification code 
     -------------------------------------  ---------------------------------- 
 b)   Nature of the transaction              Sale of Shares 
     -------------------------------------  ---------------------------------- 
 c)   Price(s) and volumes(s)                Price(s)            Volume(s) 
                                              GBP                 4,400 
                                               32.02609 
     -------------------------------------  ------------------  -------------- 
 d)        Aggregated information 
             *    Aggregate volume             4,400 
                                               GBP32.02609 
                                               GBP140,914.80 
             *    Price 
 
 
             *    Total 
     -------------------------------------  ---------------------------------- 
 e)   Date of the transaction                23 September 2020 
     -------------------------------------  ---------------------------------- 
 f)   Place of the transaction               London Stock Exchange 
     -------------------------------------  ---------------------------------- 
 
 
 Enquiries: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive                 Office: +44 (0) 1606 814 730 
  Officer 
 Paul Sandland, Acting Chief               Office: +44 (0) 1606 814 730 
  Financial Officer 
  e-mail: corporate.enquiries@dechra.com 
 
 TooleyStreet Communications 
  Ltd 
 Fiona Tooley, Director                    Office: +44 (0) 121 309 0099 
  e-mail: fiona@tooleystreet.com            Mobile: +44 (0) 7785 703 523 
----------------------------------------  ------------------------------ 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKKQBNCBKKDCB

(END) Dow Jones Newswires

September 24, 2020 05:32 ET (09:32 GMT)

1 Year Dechra Pharmaceuticals Chart

1 Year Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock